FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2908691738> ?p ?o ?g. }

• W2908691738 endingPage "3871" @default.
• W2908691738 startingPage "3853" @default.
• W2908691738 abstract "The nonlysosomal glucosylceramidase β2 (GBA2) catalyzes the hydrolysis of glucosylceramide to glucose and ceramide. Mutations in the human GBA2 gene have been associated with hereditary spastic paraplegia (HSP), autosomal-recessive cerebellar ataxia (ARCA), and the Marinesco-Sjögren–like syndrome. However, the underlying molecular mechanisms are ill-defined. Here, using biochemistry, immunohistochemistry, structural modeling, and mouse genetics, we demonstrate that all but one of the spastic gait locus #46 (SPG46)-connected mutations cause a loss of GBA2 activity. We demonstrate that GBA2 proteins form oligomeric complexes and that protein–protein interactions are perturbed by some of these mutations. To study the pathogenesis of GBA2-related HSP and ARCA in vivo, we investigated GBA2-KO mice as a mammalian model system. However, these mice exhibited a high phenotypic variance and did not fully resemble the human phenotype, suggesting that mouse and human GBA2 differ in function. Whereas some GBA2-KO mice displayed a strong locomotor defect, others displayed only mild alterations of the gait pattern and no signs of cerebellar defects. On a cellular level, inhibition of GBA2 activity in isolated cerebellar neurons dramatically affected F-actin dynamics and reduced neurite outgrowth, which has been associated with the development of neurological disorders. Our results shed light on the molecular mechanism underlying the pathogenesis of GBA2-related HSP and ARCA and reveal species-specific differences in GBA2 function in vivo. The nonlysosomal glucosylceramidase β2 (GBA2) catalyzes the hydrolysis of glucosylceramide to glucose and ceramide. Mutations in the human GBA2 gene have been associated with hereditary spastic paraplegia (HSP), autosomal-recessive cerebellar ataxia (ARCA), and the Marinesco-Sjögren–like syndrome. However, the underlying molecular mechanisms are ill-defined. Here, using biochemistry, immunohistochemistry, structural modeling, and mouse genetics, we demonstrate that all but one of the spastic gait locus #46 (SPG46)-connected mutations cause a loss of GBA2 activity. We demonstrate that GBA2 proteins form oligomeric complexes and that protein–protein interactions are perturbed by some of these mutations. To study the pathogenesis of GBA2-related HSP and ARCA in vivo, we investigated GBA2-KO mice as a mammalian model system. However, these mice exhibited a high phenotypic variance and did not fully resemble the human phenotype, suggesting that mouse and human GBA2 differ in function. Whereas some GBA2-KO mice displayed a strong locomotor defect, others displayed only mild alterations of the gait pattern and no signs of cerebellar defects. On a cellular level, inhibition of GBA2 activity in isolated cerebellar neurons dramatically affected F-actin dynamics and reduced neurite outgrowth, which has been associated with the development of neurological disorders. Our results shed light on the molecular mechanism underlying the pathogenesis of GBA2-related HSP and ARCA and reveal species-specific differences in GBA2 function in vivo." @default.
• W2908691738 created "2019-01-25" @default.
• W2908691738 creator A5005219604 @default.
• W2908691738 creator A5013935159 @default.
• W2908691738 creator A5022096672 @default.
• W2908691738 creator A5030131769 @default.
• W2908691738 creator A5031145007 @default.
• W2908691738 creator A5031636056 @default.
• W2908691738 creator A5036200880 @default.
• W2908691738 creator A5041979288 @default.
• W2908691738 creator A5062519728 @default.
• W2908691738 creator A5064419864 @default.
• W2908691738 creator A5068603027 @default.
• W2908691738 creator A5071023120 @default.
• W2908691738 creator A5073242639 @default.
• W2908691738 creator A5076734902 @default.
• W2908691738 creator A5077869340 @default.
• W2908691738 creator A5081933159 @default.
• W2908691738 creator A5084823117 @default.
• W2908691738 creator A5086510070 @default.
• W2908691738 creator A5089660556 @default.
• W2908691738 creator A5090109226 @default.
• W2908691738 date "2019-03-01" @default.
• W2908691738 modified "2023-10-15" @default.
• W2908691738 title "Species-specific differences in nonlysosomal glucosylceramidase GBA2 function underlie locomotor dysfunction arising from loss-of-function mutations" @default.
• W2908691738 cites W1010681756 @default.
• W2908691738 cites W1515901750 @default.
• W2908691738 cites W1537636371 @default.
• W2908691738 cites W1584661703 @default.
• W2908691738 cites W1968874536 @default.
• W2908691738 cites W1969611867 @default.
• W2908691738 cites W1971087846 @default.
• W2908691738 cites W1971557848 @default.
• W2908691738 cites W1981948991 @default.
• W2908691738 cites W1994945352 @default.
• W2908691738 cites W1998447342 @default.
• W2908691738 cites W2002120184 @default.
• W2908691738 cites W2002311959 @default.
• W2908691738 cites W2004541713 @default.
• W2908691738 cites W2006430824 @default.
• W2908691738 cites W2025534554 @default.
• W2908691738 cites W2026364178 @default.
• W2908691738 cites W2031241813 @default.
• W2908691738 cites W2034707421 @default.
• W2908691738 cites W2044534774 @default.
• W2908691738 cites W2044805135 @default.
• W2908691738 cites W2059054872 @default.
• W2908691738 cites W2065186120 @default.
• W2908691738 cites W2077922474 @default.
• W2908691738 cites W2089237211 @default.
• W2908691738 cites W2090243158 @default.
• W2908691738 cites W2124717330 @default.
• W2908691738 cites W2136841881 @default.
• W2908691738 cites W2155348467 @default.
• W2908691738 cites W2155953627 @default.
• W2908691738 cites W2161420542 @default.
• W2908691738 cites W2161571120 @default.
• W2908691738 cites W2162254843 @default.
• W2908691738 cites W2163527490 @default.
• W2908691738 cites W2171954574 @default.
• W2908691738 cites W2175822856 @default.
• W2908691738 cites W2208335363 @default.
• W2908691738 cites W2268767834 @default.
• W2908691738 cites W2343160100 @default.
• W2908691738 cites W2461762400 @default.
• W2908691738 cites W2569884176 @default.
• W2908691738 cites W2592012303 @default.
• W2908691738 cites W2726443977 @default.
• W2908691738 cites W2735441941 @default.
• W2908691738 cites W2743193328 @default.
• W2908691738 cites W2768179813 @default.
• W2908691738 cites W2775284732 @default.
• W2908691738 cites W2790661095 @default.
• W2908691738 cites W2804822363 @default.
• W2908691738 cites W4247177180 @default.
• W2908691738 cites W4255118548 @default.
• W2908691738 doi "https://doi.org/10.1074/jbc.ra118.006311" @default.
• W2908691738 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6422076" @default.
• W2908691738 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30662006" @default.
• W2908691738 hasPublicationYear "2019" @default.
• W2908691738 type Work @default.
• W2908691738 sameAs 2908691738 @default.
• W2908691738 citedByCount "18" @default.
• W2908691738 countsByYear W29086917382019 @default.
• W2908691738 countsByYear W29086917382020 @default.
• W2908691738 countsByYear W29086917382021 @default.
• W2908691738 countsByYear W29086917382022 @default.
• W2908691738 countsByYear W29086917382023 @default.
• W2908691738 crossrefType "journal-article" @default.
• W2908691738 hasAuthorship W2908691738A5005219604 @default.
• W2908691738 hasAuthorship W2908691738A5013935159 @default.
• W2908691738 hasAuthorship W2908691738A5022096672 @default.
• W2908691738 hasAuthorship W2908691738A5030131769 @default.
• W2908691738 hasAuthorship W2908691738A5031145007 @default.
• W2908691738 hasAuthorship W2908691738A5031636056 @default.
• W2908691738 hasAuthorship W2908691738A5036200880 @default.
• W2908691738 hasAuthorship W2908691738A5041979288 @default.
• W2908691738 hasAuthorship W2908691738A5062519728 @default.

• next